N-Acetyltransferase 2 (Arylamine N-Acetyltransferase) (NAT2) Peptide
Quick Overview for N-Acetyltransferase 2 (Arylamine N-Acetyltransferase) (NAT2) Peptide (ABIN937133)
Target
Origin
Source
Application
-
-
Peptide Type
- Synthetic
-
Sequence
- CLTEERGIWY LDQIRREQYI TNKEFLNSHL LPKKKHQKIY LFTLEPRTIE
-
Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of NAT2 antibody,
Alternative Names: NAT2 control peptide, NAT2 antibody Blocking Peptide, Anti-NAT2 Blocking Peptide, N-Acetyltransferase 2 Blocking Peptide, Arylamine N-Acetyltransferase Blocking Peptide, AAC2 Blocking Peptide, NAT2, NAT-2, NAT 2, NAT-2 Blocking Peptide, NAT 2 Blocking Peptide -
Purification
- The antibody is affinity-purified from rabbit antiserum by affinity chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide is removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
-
-
-
-
Application Notes
- Optimal conditions should be determined by the investigator
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20 °C long term.
-
-
- NAT2 (N-Acetyltransferase 2 (Arylamine N-Acetyltransferase) (NAT2))
-
Background
- NAT2 is a N-acetyltransferase 2 (arylamine N-acetyltransferase 2). This enzyme functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in its gene are reponsible for the N-acetylation polymorphism in which human populations segregate into rapid,intermediate, and slow acetylator phenotypes. Polymorphisms in NAT2 are also associated with higher incidences of cancer and drug toxicity.
-
Molecular Weight
- 32 kDa
Target
-